59/03/18 Letter from Mary Cowen to Assistant Prosecuting Attorney Gertrude Mahon

Letter from Mary Cowen at the Coroner\u27s Office re: the answer brief of Samuel H. Sheppard re: the Petition to the Supreme Court of Ohio for a Writ of Habeas Corpus. The letter addresses a card that Cowen had in her files regarding the blood-stained watches. The card was never part of the official record of the Coroner\u27s Office; it was a notation for Cowen\u27s own reference regarding the watches and blood stains. The notation, reading Turned over to Prosecutor\u27s Office (Miss Hart) 11/4/54 at 10:27 AM, referred to the watch itself; it was made solely for Cowen\u27s own information. Cowen wrote the letter to assistant prosecuting attorney Gertrude Mahon to clarify the inaccuracy about evidence and these notations (cards), which were inaccurately described in the Sheppard Answer Brief Petition to the Supreme Court of Ohio for Habeas Corpus

Current Performance Characteristics of NASA Langley Research Center's Cockpit Motion Base and Standardized Test Procedure for Future Performance Characterization

This report documents the updated performance characteristics of NASA Langley Research Center's (LaRC) Cockpit Motion Base (CMB) after recent revisions that were made to its inner-loop, feedback control law. The modifications to the control law will be briefly described. The performance of the Cockpit Motion Facility (CMF) will be presented. A short graphical comparison to the previous control law can be found in the appendix of this report. The revised controller will be shown to yield reduced parasitic accelerations with respect to the previous controller. Metrics based on the AGARD Advisory Report No. 144 are used to assess the overall system performance due to its recent control algorithm modification. This report also documents the standardized simulator test procedure which can be used in the future to evaluate potential updates to the control law

Current Performance Characteristics of NASA Langley Research Center's Cockpit Motion Base and Standardized Test Procedure for Future Performance Characterization

This report documents the updated performance characteristics of NASA Langley Research Center's (LaRC) Cockpit Motion Base (CMB) after recent revisions that were made to its inner-loop, feedback control law. The modifications to the control law will be briefly described. The performance of the CMF will be presented. A short graphical comparison to the previous control law can be found in the appendix of this report. The revised controller will be shown to yield reduced parasitic accelerations with respect to the previous controller. Metrics based on the AGARD Advisory Report No. 144 are used to assess the overall system performance due to its recent control algorithm modification. This report also documents the standardized simulator test procedure which can be used in the future to evaluate potential updates to the control law

Piloted Simulation Assessment of the Impact of Flexible Structures on Handling Qualities of Generic Supersonic Aircraft

The NASA Langley Research Center Cockpit Motion Facility (CMF) was used to conduct a piloted simulation assessment of the impact of flexible structures on flying qualities. The CMF was used because of its relatively high bandwidth, six degree-of-freedom motion capability. Previous studies assessed and attempted to mitigate the effects of multiple dynamic aeroservoelastic modes (DASE). Those results indicated problems existed, but the specific cause and effect was difficult to ascertain. The goal of this study was to identify specific DASE frequencies, damping ratios, and gains that cause degradation in handling qualities. A generic aircraft simulation was developed and designed to have Cooper-Harper Level 1 handling qualities when flown without DASE models. A test matrix of thirty-six DASE modes was implemented. The modes had frequencies ranging from 1 to 3.5 Hz and were applied to each axis independently. Each mode consisted of a single axis, frequency, damping, and gain, and was evaluated individually by six subject pilots with test pilot backgrounds. Analysis completed to date suggests that a number of the DASE models evaluated degrade the handling qualities of this class of aircraft to an uncontrollable condition

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

KT acknowledges receipt of a mandate of Industrial Research Fund (IOFm/05/022). JB acknowledges funding from the European Research Council Advanced Award 3400867/RAPLODAPT and the Israel Science Foundation grant # 314/13 (www.isf.il). NG acknowledges the Wellcome Trust and MRC for funding. CD acknowledges funding from the Agence Nationale de Recherche (ANR-10-LABX-62-IBEID). CJN acknowledges funding from the National Institutes of Health R35GM124594 and R21AI125801. AW is supported by the Wellcome Trust Strategic Award (grant 097377), the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen MaCA: outside this study MaCA has received personal speaker’s honoraria the past five years from Astellas, Basilea, Gilead, MSD, Pfizer, T2Candida, and Novartis. She has received research grants and contract work paid to the Statens Serum Institute from Astellas, Basilea, Gilead, MSD, NovaBiotics, Pfizer, T2Biosystems, F2G, Cidara, and Amplyx. CAM acknowledges the Wellcome Trust and the MRC MR/N006364/1. PVD, TC and KT acknowledge the FWO research community: Biology and ecology of bacterial and fungal biofilms in humans (FWO WO.009.16N). AAB acknowledges the Deutsche Forschungsgemeinschaft – CRC FungiNet.Peer reviewedPublisher PD

A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change

The lack of standardized criteria for measuring therapeutic response is a major obstacle to the development of new therapeutic agents for chronic graft-versus-host disease (cGVHD). National Institutes of Health (NIH) consensus criteria for evaluating therapeutic response were published in 2006. We report the results of four consecutive pilot trials evaluating the feasibility and estimating the inter-rater reliability and minimum detectable change of these response criteria

AI is a viable alternative to high throughput screening: a 318-target study

: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery

Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations

Background Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease affecting multiple body systems with wide variability in presentation. In 2013, Pediatric Neurology published articles outlining updated diagnostic criteria and recommendations for surveillance and management of disease manifestations. Advances in knowledge and approvals of new therapies necessitated a revision of those criteria and recommendations. Methods Chairs and working group cochairs from the 2012 International TSC Consensus Group were invited to meet face-to-face over two days at the 2018 World TSC Conference on July 25 and 26 in Dallas, TX, USA. Before the meeting, working group cochairs worked with group members via e-mail and telephone to (1) review TSC literature since the 2013 publication, (2) confirm or amend prior recommendations, and (3) provide new recommendations as required. Results Only two changes were made to clinical diagnostic criteria reported in 2013: “multiple cortical tubers and/or radial migration lines” replaced the more general term “cortical dysplasias,” and sclerotic bone lesions were reinstated as a minor criterion. Genetic diagnostic criteria were reaffirmed, including highlighting recent findings that some individuals with TSC are genetically mosaic for variants in TSC1 or TSC2. Changes to surveillance and management criteria largely reflected increased emphasis on early screening for electroencephalographic abnormalities, enhanced surveillance and management of TSC-associated neuropsychiatric disorders, and new medication approvals. Conclusions Updated TSC diagnostic criteria and surveillance and management recommendations presented here should provide an improved framework for optimal care of those living with TSC and their families

Assumption without representation: the unacknowledged abstraction from communities and social goods

We have not clearly acknowledged the abstraction from unpriceable “social goods” (derived from communities) which, different from private and public goods, simply disappear if it is attempted to market them. Separability from markets and economics has not been argued, much less established. Acknowledging communities would reinforce rather than undermine them, and thus facilitate the production of social goods. But it would also help economics by facilitating our understanding of – and response to – financial crises as well as environmental destruction and many social problems, and by reducing the alienation from economics often felt by students and the public

59/03/18 Letter from Mary Cowen to Assistant Prosecuting Attorney Gertrude Mahon

Letter from Mary Cowen at the Coroner\u27s Office re: the answer brief of Samuel H. Sheppard re: the Petition to the Supreme Court of Ohio for a Writ of Habeas Corpus. The letter addresses a card that Cowen had in her files regarding the blood-stained watches. The card was never part of the official record of the Coroner\u27s Office; it was a notation for Cowen\u27s own reference regarding the watches and blood stains. The notation, reading Turned over to Prosecutor\u27s Office (Miss Hart) 11/4/54 at 10:27 AM, referred to the watch itself; it was made solely for Cowen\u27s own information. Cowen wrote the letter to assistant prosecuting attorney Gertrude Mahon to clarify the inaccuracy about evidence and these notations (cards), which were inaccurately described in the Sheppard Answer Brief Petition to the Supreme Court of Ohio for Habeas Corpus